Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-309: Phase 2 randomized open-label tarlatamab dosing regimens in small cell lung cancer
jRCT2071250008Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (3 arms), sponsored by Amgen. Primary endpoints: Confirmed objective response rate, Complete response rate and 1 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071250008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250008.